The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Using integrative multiomics to explain myeloma progression and evolution of refractory disease
Ariosto Siqueira Silva, PhD, Moffitt Cancer Center, Tampa, FL, discusses work that aimed to study tumor evolution from progression to late refractory disease using integrative multiomics. Dr Silva mentions the two key epigenetic regulatory mechanisms identified by this research. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
